返回 
加入收藏
金天格胶囊联合唑来膦酸注射液治疗绝经后糖尿病骨质疏松患者的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 金天格胶囊联合唑来膦酸注射液治疗绝经后糖尿病骨质疏松患者的临床观察 |
| TITLE： | |
| 摘要： | 目的：探讨金天格胶囊联合唑来膦酸注射液对绝经后糖尿病骨质疏松患者骨密度、视觉模拟量表（VAS）评分及实验室检查指标的影响。方法：将绝经后糖尿病骨质疏松患者140例按随机区组法分为对照组和治疗组，各70例。两组患者治疗前后均给予0.9％氯化钠注射液100 ml静脉滴注，同时补充维生素D及钙剂。对照组患者给予唑来膦酸注射液5 mg静脉滴注，滴注时间＞15 min，每4周1次；治疗组患者在对照组基础上加用金天格胶囊口服，每次1.2 g，tid。两组患者均治疗6个月。比较两组患者治疗前后的骨密度、VAS评分和实验室检查指标水平，以及不良反应发生情况。结果：治疗后，两组患者各部位骨密度均较治疗前显著增高，且治疗组患者各部位骨密度均显著高于对照组，差异均有统计学意义（P＜0.05）。两组患者治疗后VAS评分均显著低于治疗前，且治疗组患者显著低于对照组，差异均有统计学意义（P＜0.05）。两组患者血钙和血磷水平与治疗前比较无变化，但骨钙素水平显著高于治疗前，骨特异性碱性磷酸酶水平显著低于治疗前，且治疗组患者骨钙素和骨特异性碱性磷酸酶水平均显著优于对照组，差异均有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：金天格胶囊联合唑来膦酸注射液治疗绝经后糖尿病骨质疏松患者可显著提高其骨密度，缓解疼痛程度，改善实验室检查指标水平，且未增加不良反应发生风险。 |
| ABSTRACT： | OBJECTIVE： To investigate the effects of Jintiange capsules combined with zoledronic acid on bone mineral density （BMD）， VAS scores and lab indexes of patients with postmenopausal diabetic osteoporosis. METHODS： 140 patients with postmenopausal diabetic osteoporosis were divided into control group and treatment group according to randomized blocks， with 70 cases in each group. Both group received 0.9％ Sodium chloride injection 100 ml intravenously before and after treatment， and were given vitamin D and calcium. Control group was given Zoledronic acid injection 5 mg intravenously for more than 15 min， once every 4 weeks. Treatment group was additionally given Jintiange capsules 1.2 g， po， tid， on the basis of control group. Both groups received 6 months of treatment. BMD， VAS score， lab indexes before and after treatment and the occurrence of ADR were compared between 2 groups. RESULTS： After treatment， BMD of 2 groups were increased significantly compared to before treatment， and the treatment group was significantly higher than the control group， with statistical significance （P＜0.05）. VAS score of 2 groups after treatment were significantly lower than before treatment， and VAS score of treatment group was significantly lower than that of control group after treatment， with statistical significance （P＜0.05）. The levels of blood calcium and serium inorganic phosphorus had no change in 2 groups； but the level of osteocalcin was significantly higher than before treatment， while the level of bone-specific alkaline phosphatase was significantly lower than before treatment， and the levels of osteocalcin and bone-specific alkaline phosphatase in treatment groups were significantly better than in control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups（P＞0.05）. CONCLUSIONS： Jintiange capsules combined with Zoledronic acid injection in the treatment of postmenopausal osteoporosis patients with diabetes can significantly increase BMD， relieve pain and improve lab index levels. Moreover， it doesn’t increase the risk of ADR. |
| 期刊： | 2016年第27卷第35期 |
| 作者： | 潘颖，郄素会，刘国强，曹俊明 |
| AUTHORS： | PAN Ying，QIE Suhui，LIU Guoqiang，CAO Junming |
| 关键字： | 金天格胶囊；唑来膦酸注射液；绝经；糖尿病；骨质疏松 |
| KEYWORDS： | Jintiange capsules； Zoledronic acid injection； Postmenopausal； Diabetes； Osteoporosis |
| 阅读数： | 845 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
